Giannis Mountzios
@g_mountzios
#MedicalOncologist# MSc Transl Res Univ Paris Sud #LungCancer# biology, immunotherapy, clinical trials #LCSM# @myESMO faculty @iaslc live to give
1.4K Following 3K Followers
Can T-cell engagers create a "tail of the curve" phenomenon in #SCLC#, in a way similar to ICIs?
Apparently yes!
Long-term Follow-up (22m) of the Dellphi-304 trial as published in @Annals_Oncology and reported in #ESMO2026# by @charlesrudin show 30% pts alive at 2 yrs with tarla compared to 15% with chemo. Sustained disease control for ≥52 weeks was observed in 24.4% versus 4.3%.
Confirmatory results of prolonged tarla efficacy, giving hope to our patients
@SclcSMASHERS @SCLCYIForum @LungCancerEu
@YoungLungCancer @myESMO @IASLC @ASCO
Show more
